



Erratum for Marrero Rolon et al., “Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of *Helicobacter pylori* and Genotypic Markers of Clarithromycin Resistance Directly from Stool”

Rebecca Marrero Rolon,^{a,b} Scott A. Cunningham,^b Jayawant N. Mandrekar,^c Erin T. Polo,^d  Robin Patel^{b,e}

^aDepartment of Pathology, Clinical Microbiology, Montefiore Medical Center, Bronx, New York, USA

^bDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA

^cDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA

^dTIB MOLBIOL, Adelphia, New Jersey, USA

^eDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA

Volume 59, no. 5, e03040-20, 2021, <https://doi.org/10.1128/JCM.03040-20>. Page 3, Table 1: the “Sequence (5′–3′)” entry for Hpylori TM3 should read “TEX-TGGAGGTGAAAAXTCCTCCT ACCCG-phosphate.”

Copyright © 2022 American Society for Microbiology. All Rights Reserved.

Address correspondence to Robin Patel, patel.robin@mayo.edu.

The authors declare a conflict of interest. Dr. Patel reports grants from Merck, ContraFect, TenNor Therapeutics Limited and Shionogi. Dr. Patel is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, and Qvella; monies are paid to Mayo Clinic. Dr. Patel is also a consultant to Netflix. In addition, Dr. Patel has a patent on *Bordetella pertussis/parapertussis* PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel receives an editor's stipend from IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Scott A. Cunningham reports receiving an honorarium from the Antibiotic Resistance Leadership Group.

Published 16 February 2022